February 16, 2023
Japan’s key reimbursement policy panel on February 15 approved the results of cost-effectiveness assessments (CEAs) for Janssen Pharmaceutical’s Darzquro (daratumumab + vorhyaluronidase alfa) and Astellas Pharma’s Padcev (enfortumab vedotin), both cancer medicines. Darzquro is expected to see its price unchanged,...read more